Eye Infections Treatment Market Experiences Strong Growth Trajectory, Anticipates Reach of US$9.9 Billion by 2030, to grow at a CAGR of 3.8%

Global Eye Infections Treatment Market revenue is anticipated to reach US$ 7.3 billion in 2022, and the market is anticipated to grow at a CAGR of 3.8% from 2022 to 2030. By the end of 2030, it is anticipated that the market for treating eye infections will be worth US$9.9 billion.

Rising Caseloads

Caseloads of ocular surgical conditions such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are growing due to sedentary lifestyle habits, and expanding geriatric cohort. According to the US statistics 2021, cataracts affect over 24 million Americans aging at least 40 years.By age 75, about half of the Americans suffer from cataract. Further, diabetic retinopathy affects nearly 7.7 million Americans aging at least 40 years. In similar fashion, there were 48,229 corneal transplants performed in the US in 2015.

Secure your sample report enriched with captivating data visualizations. @ 
https://www.futuremarketinsights.com/reports/sample/rep-gb-1300

Key Takeaways of Eye Infection Treatment Market Study

Antibiotics would contribute over 55% revenue share in the eye infection treatment market owing to their use in treating primary eye infections and post-surgical eye infections.
Eye drop sales capture over 60% market share in the eye infection treatment market.
Conjunctivitis would account for a third of eye infection treatment demand through 2030.
Bacterial infections continue to account for over 3/5th market share.
Hospitals and retail pharmacies collectively generate over 70% total returns to shareholders.
Increasing rate of eye surgeries and rising usage of contact lenses continue to push North American market. European market would be upheld by the expanding geriatric pool.

Development and Licensing Deals with Multiple Commercialization Partners

Technology developers are laying greater emphasis on developing of novel ophthalmic formulation technologies and engaging with commercialization partners with licensing-out proprietary ophthalmic technologies.

For instance, Nicox S.A. has licensed out ZERVIATE (cetirizine ophthalmic solution) 0.24% to Eyevance Pharmaceuticals LLC for commercialization of ZERVIATE in the US. ZERVIATE is the first topical ocular formulation of antihistamine cetirizine approved for treatment of ocular itching associated with allergic conjunctivitis. In addition, Ocumension Therapeutics is responsible for all development and commercialization activities in Chinese market for ZERVIATE.

Demand for Eye Infection Drugs to Slump Amidst COVID-19 Pandemic

The coronavirus (COVID-19) pandemic has resulted in widened gap between supply and demand of eye infection treatments. As such, it has significantly reduced ocular surgery rate for short-term basis and, in turn, post-operative eye infections.

According to World Health Organization (WHO), national healthcare resources redirection and utilization to contain COVID-19 pandemic is expected to delay and reschedule the treatment of non-critical healthcare conditions for brief period, including eye care services, and ocular surgeries.

Key Segments Of Eye Infections Treatment Industry Survey By

-Drug Class
-Antibiotics
--Sulfonamides
--Macrolides
--Erythromycin
--Chloramphenicol
--Aminoglycosides
--Fluoroquinolones
--Vancomycin
--Tetracyclines
-Antivirals
--Thymidine-Based Nucleoside Analogues (Trifluridine)
--Thymidine Phosphorylase Inhibitors (Trifluridine)
--Acyclic Nucleoside Analogue of 2'Deoxyguanasine (Ganciclovir)
--Acyclic Guanine Nucleoside Analog (Acyclovir)
--Others
-Antifungals
--Polyenes (Amphotericin B (AMB) And Natamycin (NTM))
--Pyrimidines
--Echinocandins (Caspofungin (CFG) and Micafungin (MFG))
--Others
-Antihistamines
-Corticosteroids
-Glucocorticoids

Get Ahead with Comprehensive Information - Purchase Today! @
https://www.futuremarketinsights.com/checkout/1300

By Dosage Form :

-Eye Infections Treatment Tablets
-Eye Infections Treatment Capsules
-Eye Infections Treatment Ophthalmic Ointments
-Eye Infections Treatment Eye Drops
-Others

By Indication :

-Eye Infections Treatment for Conjunctivitis
-Eye Infections Treatment for Keratitis
-Eye Infections Treatment for Endophthalmitis
-Eye Infections Treatment for Blepharitis
-Eye Infections Treatment for Stye or Sty (Hordeolum)
-Eye Infections Treatment for Uveitis
-Eye Infections Treatment for Cellulitis
-Eye Infections Treatment for Ocular Herpes

By Causative Agent :

-Virus
-Bacteria
-Fungus
-Allergens

By Distribution Channels :

-Hospital Pharmacies
-Retail Pharmacies
-Online Pharmacies
-Drug Stores

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Access Report, Gain Complete Understanding: @
https://www.futuremarketinsights.com/reports/eye-infections-treatment-market

This release was published on openPR.